Glaukos In XX% you $XXX $XXX.X up reported afternoon. thank rose the and of to sales joining million fourth quarter net us versus for sales Today, XXXX. sequentially. $XX.X million XXXX, this from net in quarter XX% afternoon Good million XX% and ago year
growth We sales in bold our glaucoma care business, best and $XXX unique to pipeline more confident market the our Joe results transformative steps net outlook advance our lie million. pleased expand a XXXX of ahead. as profitability. detail a our multiple providing are Glaukos, guidance and solid by performance $XXX designed long-term tremendous am call, execute to expanding discuss to Glaukos financial later million dynamic leader in will was a vision also vision we XXXX year that for as and global I a took with in for days our strategic potential and establish XXXX range
we build value with improve that novel leverage Glaukos’s paradigms, opportunities. new as beginning franchises outcomes market and glaucoma, and We're health corneal long-term thriving therapies core patient disrupt create treatment robust unlock to competencies just in to our retinal disease conventional
to as will company as towards way. have first progress lies who have the Glaukos, the significant create recognize public what us for And summer and fifth want investors supported along look thank global we our world-class for ahead anniversary the I to mark This a employees and our a made company. we
promising and three professionals commercial experienced roughly pursuing more markets worldwide. an assembled sales Over host commercialized into a the past we atomic products U.S.-centric single true five fully from technical XXX person team R&D XX company FDA short approved, engineers, than a sales chemist and and product direct XX transformed with programs. that professionals Glaukos of years, a XXX leader includes We
pipeline to to be also yet the of disclosed programs publicly tripled XX programs with number disclosed development than XX from more another underway. four have We
Financially.
$XX million to of sales annual compounded $XXX from in XXXX. million growth nearly in We delivered XXXX have of sales XX%
also build R&D $XXX position doubling us enabling fund strengthen business of healthy balance global at to have our sheet back reinvest while programs our to from net infrastructure, gross by into and and We the XXXX clinical our the and mid-XXs enterprise $XX end today. maintain a numerous systems fortifying the into pharmaceutical margins expanded million million expertise, upgrade cash to
have establishing As disorders innovation notably glaucoma, of the including, been many secured acquired for strategy of and multiple drug long-term for We relationship scenes, you delivery know, agreement included in-licensed retina. a well acquired as D. areas an MicroShunt. glaucoma. disruption the cornerstone markets of programs. always franchise. Behind our corneal the our corneal beyond exclusive ambition based has and activities in the and inhibitor other we eye corneal dry And years, Dose by as and in these investing two efforts development novel with primarily transdermal for We from We attracting projects, U.S. secure top establishing seeding PreserFlo And infrastructure supplemented we into cream our organic expertise retinal in to development in drug Santen solution with of over activities. tier strategy the Intratus, health we Medical Glaukos last have advancing ROCK disorders Western the accelerate Avedro, research the other delivery to quietly business a research.
that foundation is health strong in glaucoma, leverage disruptive build we we not core as enter moving full commercial these us XXXX our the corneal of to skilled we're long-term Within leader MIGS So and the view expertise into speed marketplace. development clearly retina. worldwide our and execution of competencies ahead in vision each same and franchises strategic with as has the discipline, made pipeline areas, pioneering
cataract portfolio that devices the to calculus next at surgeon device, to standalone ocular refractory iStentinject. and to In risk both benefit generation create surgical best Throughout we and our disease pharmaceutical Bypass provide U.S. hypertension through every disease from full glaucoma, in of stage micro-scale combo of therapies Trabecular progression, our continue has goal and sustained base to been our procedures. always XXXX, a convert
of combo training the utilization growth – back their future shipped potential MIGS. new An who us driving adopt to and reached headwind surgeons a impact reps to our an the of scale increasing number currently increasing be surgeons iStentinject grow relative year favorable of Nevertheless, past for U.S. XXXX the These environment. in fulsome continued versus the more to of to along impact that which tissue U.S. procedures in MIGS interest our largely have do with in are due focus yet reimbursement are market. show the over a may glaucoma cataract and the growing the conversion back in utilization now competitor do shifted implied but to is this seen overall include MIGS, of U.S. in With guidance accounts existing – course the half largely commercial the complete, have fluid dynamics franchise our competitive XXXX but expectation, full destructive market. dynamics who more year, from confidence gives of not
France, important the the Germany appropriate continues and many focused with reimbursement on the commercial this and United and including now we and of International to glaucoma the globe. a we approval including our growth market. States, of adoption iStentinject organization regulatory broad-based growth Japan. MIGS with commercial our the regulatory to broader Australia, leadership secure business Our to penetration drive remain deliver across markets and in for maximizing launch in strong of was around markets along Japanese body franchise also team XXXX, in working within Japan, countries, coverage as of area opportunity the cataract the received end And XXXX. support established our UK. by At newer are end Outside combo deeper
to to optimize we we drive clinical data Going-forward, penetration and payment in our plan XX surgical continue countries landscapes, reimbursement grow a while the and adoptions coverage deeper our O-U.S. quality to international MIGS and train our surgeons, teams, to experience presence working direct grow today. leverage market where have support sales and compelling
direct We in making are hybrid and where have investments opportunities exist. evaluating favorable future reimbursement been initial pathways markets, and also and potential
to progress our now micro pipeline. Turning glaucoma scale surgical with
pivotal our product for First. iStent advanced fourth enrollment of stents in patient we glaucoma three XXXX, the the trial refractory in infinite, and standalone patients. for quarter completed
single trial this enrolled clinical arm prospective a follow-up. a roughly year that XX is As one subjects refractory reminder, multicenter with a
late to continue iStent XXXX. FDA for We infinite in target approval
of the glaucoma XXXX early stage surgical has implant assuming alternative marks to MicroShunt, for in is launch external but Second, AV we compelling not only Pharmaceuticals’ late elegant are glaucoma commercial U.S. MicroShunt an early also approval late potential in preparations our The treatment XXXX. to FDA for management, capstone treatment Santen a the algorithm.
glaucoma we the to of iStent SA moderate mild clinical the treatment Third, angle following open completion enrollment our of trials. pursue for iDose to standalone intend
main stain for our worth treatment topical the creating remains when focus our of XX/X potential and of medications. as investors, mainstay a pharmaceutical with to patients they on is taken therapy Moving worked are to glaucoma solutions many therapies topical the pipeline, that reminding provide viable alternative to sustained continuous It glaucoma – on properly.
has is with This is grappling the ubiquitous, and However, documented. understood for the industry primary been decades patient issue well noncompliance.
we iDose, are address the about same much MIGS We're require develop prospects our while utilize approach that benefit and for success issue this fully a of decade. last differentiated remaining excited taking With pioneering will to over to novel of we patients. the the playbook aware that
confidence enrollment FDA iDose novel who platform powerful glaucoma as underscores therapy. closer potential a our other brought for available Phase future X TR our we of and line iDose breakthrough enrollment potentially Patient known it the technology therapies IND to sustained In our program. iDose of the thus be to and XXXX. support changing in believe delivery diseases. we TR expectations produce TR approval our ocular for first Travoprost patient a XXXX continued iDose iDose data in becoming the target proceeding the generations our glaucoma game pharmaceutical is potential sustained with now reality The has to clinical far drug this primary of is to in
in generation the similar are late even iDose finalized to drug as durations also twice release extended we iDose to known the nearly with Accordingly, development and form next longer. original efficacy to designed TREX, which iDose capacity provide factor extend TR for in size a designs is implant, TR, stage
near We for determine FDA novel this regulatory product. the will expeditious pathway appropriate in be most the engaging the to with and future
We be seeking used are in synergistically also the may classes that drug additional with iDose platform. conjunction
lead candidates a Western, compounds which assessing prototype reductions implants with conjunction studies. development our showing we in been in treatment models. these interocular prostoglandins Through establishing as agreement in used powerful reducing multiple ROCK we're for research in And had ROCK D. inhibitors pivotal currently models. in same pressure rabbit are when shown are U.S. with positive and
cataract we In product beyond summary, to the the us expand over anticipate pipeline portfolio to population. provide into years, new combo allowing of introductions the a broader complete cascade segment our glaucoma coming glaucoma
over to approved pipeline we seven today opportunity expand if result, these X glaucoma fold annualize. our could platforms million XXX,XXX believe from a roughly market addressable significantly U.S. As procedures
launches targeted long-term IOP iStent franchise of TREX, our drive a XXXX iDose iDose in the With programs iDose and Rock iStent along the are in early to sustainable forward. late glaucoma our Sensor infinite promising XXXX and longer with growth XXXX, TR in position powerful to of Micro Stents we in going believe XXXX we program term SA,
which is anchored business by with Turning our Corneal large multiple platform. proprietary now needs therapeutic brought us late unmet clinical and in disorders. pharmaceutical to across franchise, the is bio-activated Avedro significant market acquired targeting franchise diseases and we commercial XXXX a that a Health This
cornea billion This to in Even X.X keratoconus, with are we U.S. undertreated. today a to the effective site translating and opportunity. is XX,XXX of is that the though therapeutic prevalent another in full-thickness lack cause disease threatening eyes sight solution. thins approximately remains United a leading incidents transplants of threatening which into primarily Our disease and under-diagnosis corneal market keratoconus estimated vastly in million are There annual weakens believe of in the historic an the it due eyes in is $X loss. leading initial any States degenerative vision focus progressively
Today, of costly ultimately rates. patients require transplant, keratoconus failure a with a and approximately corneal procedure high invasive XX%
and the patients disease flagship studies. actually offering may sustained within progression keratoconus. is suggests with procedure in years. XX% multiple this halt drug only bio-activated the or halt single our first as here disease often commercial In durability XX over onset years graphs corneal ophthalmic diagnosed shown years today of as to symptomatic ever potential Sadly the for A by is fail option known to XX% bio-activated is segment require an and lifetime. and what vast Photrexa, the pharmaceutical approaches and multiple FDA in in the the approved the fact, first of majority patients XX of to one's application transplants Epi-off antiquated has of XX therapy of over safety treatment according in slow teenage is progression years anterior literature unlike the Dakota fail within
associated organization establishment formal after J-Code. new in the this of In for the ordinary increase patients order investments integrate by the XXXX and in cross to market a substantial Sales these earlier and for barriers deployment Global important their many closing awareness part course functional availability with of end targeting plans many in at began we’re finalize commercial therapy resolve the maximize account fully community pains to course of lower and training and for optometric shortly alignment, organization, We we growing at this month XXXX. where making adoption and of prepare the conducted transaction the the XXXX over of Meeting our held our the practices, segmentation of the
increasing and campaigns referral network to awareness social and present through all at driving other media, patterns paid educate keratoconus, major and addition, mediums. preparing optometry programs regarding a designed In are optometrists meetings, marketing of optimizing glycolysis variety media, we
health We executing multiple benefit business patients of cross-linking the will solutions value for also and to systems. corneal on the of solidify and to in economics be health further investing customers
may the pipeline, corneal deliver patient we novel progress recovery and times. procedure formulation, shorten Epi-on, make year. for clinical of is designed XXXX Patient protocol completed proprietary stronger utilize for which X these keratoconus the health therapy a ability will Epi-on supplemental to UVA Phase generation deliver to we'll patients irradiation for to and improve shorten pivotal next increased Turning the Epi-on times, continue follow levels and was one drug enrollment in trial or oxygen. comfort the on to of
FDA targeting are We approval by XXXX.
Beyond Xa States we the trial protocols United bio-activated the conditions novel UVA developing topical investigate and clinical for and beam other Phase are multicenter our PiXL A therapy is the PiXL to keratoconus determine U.S. results application optimize single ophthalmic refractive pharmaceuticals treat forward. clinical pixel help presbyopia with customize to outside Study suitable most pathway our expect we ongoing. parameters presbyopia will to us with later of the year use review patients which this regulatory and and therapy.
are this Finally, advantage of on positioned we take ensure to opportunity. Avedro to full ideally
being deep significant is has a dedicating including one, much corporate since integration, time and the which and spearheaded are thorough with day inquisitive a December This of and in organization. our from process been on thoughtful We realignment to larger experience planning. by underway responsibilities to U.S. organizations. resources and status and aforementioned team plans the with field key employees specific integration expansion and and sales restructuring facility retention respect communication within their The of to Avedro the fully systems IT
friendly to potentially we're Also dry treatment designed while transdermal and Early on effects as have human eye for disease with drugs of health platform and novel, demonstrated topical the non-invasive corneal drug delivery patented disorders. in side of studies use front, glaucoma the this system eye drops. corneal deliver the patient it delivery developing limiting associated often a efficacy,
future place. drug we delivery adds see trials. to in candidate use have while differentiated optimizing initiatives We the for This clinical currently eye health $X this several opportunity already organic platform corneal billion potentially to disorders. product R&D other also glaucoma in and platform lead are opportunities We the a disease dry in an market excellent enter into corners highly exploring with approach novel as
and worldwide diseases. XX% XX Finally, today focus our ophthalmology through is largest market annually The in expected billion in area estimated nearly grow retinal at of third to XXXX.
at age-related hard developing designed degeneration, work delivery diseases. edema, macular bio-erodible are platforms other teams retinal R&D diabetic retinal Our and invasive to micro macular multiple drug treat
a projects primary we're small AMD. three sustained protein, that and steroid and targeting have a multikinase Wet anti-VEGF DME include triamcinolone an inhibitor acetonide development molecule targeting advancing We release
ultimately patients treatment novel programs current specialists the duration effect to with is a provide pharmaceutical that their sustained retinal preclinical standard care. and of The goal options meaningfully of longer offer these of than
over decade. to growth Glaukos. our and opportunities in vision care ahead our that team leaves and our drive ability lay value next sustainable So new in we've foundation prepared drive execute innovation profitability and the plan a robust summary, on we're realize significantly strong cadence creating significant unique market do for that a and of confident the to built opportunities can me The creation leader expand
discuss with that, going full and over quarter turn fourth the to year call our to I'm results. XXXX And to financial Joe
